Management of Focal Epilepsy with Lamotrigine and Oxcarbazepine

Introduction to Lamotrigine and Oxcarbazepine

The American Academy of Neurology recommends that lamotrigine and oxcarbazepine can be used together or sequentially with caution, as they have distinct metabolic pathways resulting in minimal pharmacokinetic interactions 1, 2

Unlike the interaction between lamotrigine and carbamazepine, oxcarbazepine does not significantly alter lamotrigine metabolism, according to the MMWR Recommendations and Reports 1, 2

Patients with prior severe reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), should be cautious when using lamotrigine and oxcarbazepine, as there is potential cross-reactivity within the anticonvulsant class 3
Genetic predisposition, such as HLA-B*15:02 in Han Chinese populations, increases the likelihood of lamotrigine-induced SJS/TEN, according to the Translational Neurodegeneration journal, which may be associated with neurology guideline societies 4

For patients with prior mild skin reactions, cautious introduction of the alternative medication with slow titration and close monitoring for early signs of hypersensitivity is recommended 3
For patients with prior severe reactions, considering avoiding both medications due to potential cross-reactivity and considering genetic testing for HLA-B*15:02 in high-risk populations is advised 3
Consider HLA-B*15:02 screening before initiating treatment in patients of Han Chinese descent, as recommended by the Translational Neurodegeneration journal, which may be associated with neurology guideline societies 4

The severity of SJS/TEN should be assessed using SCORTEN (SCORe of Toxic Epidermal Necrolysis), and for severe cases with extensive epidermal detachment (>10% BSA), admission to a specialized intensive care unit or burn center with a multidisciplinary team approach is recommended by the British Association of Dermatologists 5
Supportive care, including fluid management, wound care, pain control, and monitoring for complications, is essential in the management of SJS/TEN, as suggested by the British Journal of Dermatology, which may be associated with the British Association of Dermatologists 5
Patient education about early warning signs and symptoms, as well as regular monitoring during the initial treatment period, is crucial in preventing SJS/TEN 5
Documentation and reporting to pharmacovigilance authorities is essential in cases of lamotrigine-induced SJS/TEN, as stated in the British Journal of Dermatology, which is associated with the British Association of Dermatologists 5

Alternative anticonvulsants like levetiracetam or pregabalin may be safer options for patients with prior severe reactions to lamotrigine or oxcarbazepine, according to the Chest guidelines 3

The combination of lamotrigine and oxcarbazepine demonstrates additive anticonvulsant effects in experimental models, but more frequent adverse events occur with combination therapy compared to monotherapy 3